Last reviewed · How we verify
Oral N-Acetyl Cystein — Competitive Intelligence Brief
phase 3
antioxidant and mucolytic
Respiratory
Small molecule
Live · refreshed every 30 min
Target snapshot
Oral N-Acetyl Cystein (Oral N-Acetyl Cystein) — Imam Khomeini Hospital. N-Acetyl Cysteine acts as an antioxidant and mucolytic agent by replenishing intracellular glutathione levels and breaking disulfide bonds in mucus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Oral N-Acetyl Cystein TARGET | Oral N-Acetyl Cystein | Imam Khomeini Hospital | phase 3 | antioxidant and mucolytic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (antioxidant and mucolytic class)
- Imam Khomeini Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Oral N-Acetyl Cystein CI watch — RSS
- Oral N-Acetyl Cystein CI watch — Atom
- Oral N-Acetyl Cystein CI watch — JSON
- Oral N-Acetyl Cystein alone — RSS
- Whole antioxidant and mucolytic class — RSS
Cite this brief
Drug Landscape (2026). Oral N-Acetyl Cystein — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-n-acetyl-cystein. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab